Your browser does not support JavaScript or it may be disabled!
 India As It Happens
Rediff Labs will showcase innovative products that rediff is working on behind the scenes.
News   |   Images
Get Realtime News
on your webpage

About 720 results for "Tecfidera"

Opinion/decision on a Paediatric investigation plan (PIP): ...

| 30 Churchill Place, Canary Wharf, London E14 5EU, United Kingdom . Tel. +44 (0)20 3660 6000 . Fax +44 European Medicines Agency, 1 month ago

17 images for Tecfidera

FiercePharma, 1 month ago
Bidness Etc, 2 months ago
Motley Fool, 4 months ago
European Pharmaceutical Review, 4 months ago, 4 months ago
Nasdaq, 4 months ago
Nasdaq, 4 months ago
Nasdaq, 4 months ago
Nasdaq, 4 months ago, 4 months ago

BRIEF-Biogen CEO to step down; sees FY rev of about $11.2-$11.4 bln

July 21 Biogen Inc Sees 2016 Gaap And Non * George a. Scangos, ph.d., to step down as CEO * Biogen inc says Q2 Tecfidera revenue of $987 million versus. $883.3 million in the same quarter last year * Sees 2016 non-gaap diluted eps is ...
 Reuters UK1 month ago Biogen CEO Scangos to step down, raising questions about the Big Biotech's future  FiercePharma1 month ago Biogen CEO Scangos to Step Down -- WSJ  Nasdaq1 month ago Biogen : Announces CEO Search, Lifts Guidance--2nd Update  4 Traders1 month ago

Human medicines European public assessment report (EPAR): Tecfidera, dimethyl fumarate, Revision: 7, Authorised

This is a summary of the European public assessment report (EPAR) for Tecfidera. It explains how the Agency assessed the medicine to recommend its authorisation in the EU and its conditions of use. It is not intended to provide practical advice on ...
 European Medicines Agency1 month ago

Biogen Optionality Looking Attractive; Bernstein Initiates At Outperform

Biogen Inc (NASDAQ: BIIB ) has an aging MS franchise, but a solid biosimilar pipeline is sure to offset the loss of Tecfidera, Avonex and Tysabri. Bernstein's Aaron Gal initiated Biogen at outperform and set a price target of $282. The multiple ...
 Benzinga.com1 month ago

Biogen's top commercial exec leaves amid Tecfidera sales trouble

When a top biopharma executive abruptly shoves off, what comes next? Questions. Make that departing exec a sales-and-marketing chief, and couple that departure with slowing sales of a key product, and the questions multiply. Tony Kingsley That's ...
 FiercePharma1 month ago

Onset of Parkinson's Disease May Be Slowed by Metabolite in MS Drug, Mouse Study Shows

Dimethylfumarate (Tecfidera), a drug used to harness multiple sclerosis symptoms, generates a metabolite that could be used in Parkinson's patients to improve defenses against oxidative damage. The drug actson Nrf2, a molecule that has frequently ...
 Parkinson'sNewsToday.com2 months ago
American Banking News - Forex

Robert W. Baird Reaffirms Neutral Rating for Biogen Inc. (BIIB)

Robert W. Baird restated their neutral rating on shares of Biogen Inc. (NASDAQ:BIIB) in a research report released on Wednesday. The brokerage currently has a $284.00 target price on the biotechnology company's stock. In other Biogen news, CEO ...
 WKRB News1 week ago Biogen Inc. (BIIB) Earns Hold Rating from Leerink Swann  Mideast Time2 weeks ago Biogen Inc. (BIIB) Upgraded by Zacks Investment Research to Buy  WKRB News2 weeks ago Biogen Inc. (BIIB) Lowered to Hold at Zacks Investment Research  Mideast Time2 weeks ago

Biogen Inc. (BIIB) Position Raised by Patton Albertson Miller Group LLC

Patton Albertson Miller Group LLC boosted its position in shares of Biogen Inc. (NASDAQ:BIIB) by 5.4% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 2,659 ...
 Mideast Time1 week ago Stanley Laman Group Ltd. Purchases Shares of 3,466 Biogen Inc. (BIIB)  Mideast Time2 weeks ago Biogen Inc. (BIIB) Shares Bought by Reynders McVeigh Capital Management LLC  Zolmax News2 weeks ago Biogen Inc. (BIIB) Position Held by Loring Wolcott & Coolidge Fiduciary Advisors LLP MA  WKRB News1 week ago
American Banking News

Research Analysts Upgrades for August, 12th (BABA, BBRY, BCRX, BIIB, DRX, DRXGY, FIX, LDBKY, PBH, TUWLF)

Alibaba Group Holding (NYSE:BABA) was upgraded by analysts at Raymond James Financial Inc. from an outperform rating to a strong-buy rating. The firm currently has $124.00 target price on the stock, up from their previous target price of $95.00. ...
 American Banking News2 weeks ago Investment Analysts Upgrades for July, 27th (AAPL, ADI, BIIB, CHK, COH, CUZ, CWEI, DISCA, ESRX, MBLY)  American Banking News - Earnings1 month ago
Bidness Etc

Medical Affairs Reputation: Multiple Sclerosis (EU5)

NEW YORK , Aug. 11, 2016 /PRNewswire/ -- MS medical affairs: oral therapies outperforming in Europe . How does your team measure up? In Europe's Multiple Sclerosis (MS) market, medical affairs teams for oral therapies outperform their ...
 International Business Times2 weeks ago 5 Things a Neurologist Wants You to Know About Multiple Sclerosis  EverydayHealth.com2 weeks ago Multiple Sclerosis: Progress, but No Cure  Pharmscope2 weeks ago MS sufferers being made to wait for treatment as medication is not available  Times of Malta2 weeks ago
Prev | Next
Personalize your Realtimeclose [x]
Add content to your personalized tab - My News
Add upto 6 topics of your interest:
for eg.2g Scam , World
Personalize the tabs display. ( You can add or remove the tabs )
AlertsGet updates on latest news & your favourite topics right in your inbox.Set an Alert|Manage your Alerts


Realtime News

on your Webpage

Add Widget >Get your members hooked!
Related Queries - Tecfidera
Get updated on latest news & your favorite topics right in your inbox!
More     Less